MAPT and Alzheimer disease: Alzheimer’s disease (AD) is a progressive brain disease with a specific onset of age-related cognitive and functional decline leading to death[1] characterized by pathology of excessive accumulation of amyloid-β (Aβ) and tau protein, neuronal and vascular damage, reduced cerebral glucose metabolism.[2,3] Its symptoms are often characterized by significant memory loss and deficits in executive function, visuospatial ability, and attention.[4]